OncoMatch/Clinical Trials/NCT06613217
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Is NCT06613217 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies zelenirstat for relapsed adult aml.
Treatment: zelenirstat — This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Kidney function
eGFR >60 mL/min (Cockcroft-Gault); creatinine ≤ 1.5x ULN
Liver function
Total bilirubin ≤ 1.5x ULN unless due to hemolysis or congenital disorder; ALT and AST ≤ 2.5x ULN or ≤ 5x ULN for patients with malignant liver involvement
Cardiac function
Adequate cardiac function per institutional normal measured by echocardiography or MUGA (LVEF ≥ 50%)
Patients must have adequate liver function as assessed by the following laboratory tests... Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) unless increase is due to hemolysis or congenital disorder such as Gilbert's syndrome; ALT and AST ≤ 2.5 times ULN or ≤ 5 times ULN for patients with malignant liver involvement. Patients must have adequate kidney function, as assessed by both: the estimated glomerular filtration rate (eGFR) >60 mL/min... creatinine ≤ 1.5 times the ULN. Adequate cardiac function per institutional normal measured by echocardiography or multi-gated acquisition (MUGA) scan (Left ventricular ejection fraction (LVEF) ≥ 50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Centre · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06613217 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages